NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report issued on Monday morning,Benzinga reports. They currently have a $19.00 price objective on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.75) EPS and FY2025 earnings at ($0.08) EPS.

A number of other brokerages have also recently commented on NRXP. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 12th.

NRx Pharmaceuticals Trading Up 1.6 %

NASDAQ:NRXP opened at $1.29 on Monday. The company has a market capitalization of $15.60 million, a P/E ratio of -0.61 and a beta of 1.27. The business’s 50-day moving average is $1.38 and its 200 day moving average is $2.14. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.